FDA approves Hernexeos as first oral therapy for NSCLC with HER2 mutations
previous post
About Medical Newswire™ aggregates, publishes and distributes news about the medical industry. In association with EmailWire, Medical Newswire™ provides press release distribution services in the medical sector. Press releases are disseminated to journalists, experts, investors, trade publications and other related media outlets. For more information, contact us at these messaging apps:
Mobile/WhatsApp: +1832-716-2363
Skype: groupwebmedia
Telegram: @groupwebmedia
Medical Newswire™ is part of GroupWeb Media Network. © 2026 GroupWeb Media LLC